Evolent Health Q2 revenue beats expectations
EVH•Outlook
- Evolent raises 2026 revenue guidance to $2.6-$2.7 bln
- Company tightens 2026 Adjusted EBITDA guidance to $120-$135 mln
- Evolent expects 2027 revenue growth of over 25% versus 2026
Overview
- US healthcare solutions firm's Q2 revenue rose and beat analyst expectations
- Company posted a net loss for Q2, but loss narrowed from prior year
- Full-year 2026 revenue guidance raised, adjusted EBITDA outlook tightened
Result drivers
- Specialty care demand - Co said rising medical costs for health plans drove robust demand for its complex specialty care solutions, especially oncology
- New and expanded partnerships - Co highlighted new Oncology Performance Suite partnership and expanded Specialty Technology & Services Suite contract as contributors to growth
- Higher medical costs - Co reported a higher medical expense ratio, reflecting increased medical costs relative to revenue
Key details and analyst coverage
| Metric |
|---|
